About RegeneRx Biopharmaceuticals.

About RegeneRx Biopharmaceuticals,is RegeneRx accelerate the discovery and development of novel molecules, tissue and organ repair concentrated Currently RegeneRx development of three drugs-RGN. 137, RGN-259 and RGN-352 are for dermal, ophthalmic and cardiovascular – wound healing. These drugs are on T? a 43 – amino acid peptide, in part through an exclusive worldwide license from the National Institutes of Health. Preliminary investigations show that T 4 prove effective in multiple indications;? Therefore RegeneRx developed several drugs as part of a broad therapeutic platform. Ofds over 60 worldwide patents and patent applications relating to the skin, eyes and internal wounds and tissue repair, cardiac and neurological protection and injuries, septic shock and several consumer product areas.

‘These studies have new and important potential cardiac risks associated with BPA exposure particularly important for women particularly important for women ‘s heart health ‘identified associated, he added.Dept. Of Fibrosis: One Success Story partly completedCystic fibrosis is the leading life – threatening genetic disease affecting people northern European descent. In Great Britain, it affects about a newborn at the 2,400th Babys born in to the disease, if not addressed it can not digest their food as a rule, no to thrive, and meet strict, repeated and chronic infections of lungs, which is the usual cause of death. When CF first described in the 1930s, had a life expectancy of less than five years ago.

Increase tenfold since 1940 more than 8.000 Title of the original article: Cystic fibrosis mortality and surviving in the UK: 1947-2003.

These forecasts and the recommendations of the with FDA Vaccines and Related Products Advisory Committee to of FDA determines basis the three strains The elderly, should include to their vaccines to U.S. Population. Closer the consistency between the circulating strains and which stems in vaccine , the better is to protect against the disease..